Albumin fusion proteins
OwnerCraig A. Rosen, William A. Haseltine +1inventors
InventorsCraig A. Rosen, William A. Haseltine, Steven M. Ruben
Life of this patent
Estimating the term…
Loading patent…
OwnerCraig A. Rosen, William A. Haseltine +1inventors
InventorsCraig A. Rosen, William A. Haseltine, Steven M. Ruben
Estimating the term…
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.
-32. (canceled)
A method of treating a human comprising administering to said human an effective amount of a pharmaceutical composition comprising an albumin fusion protein comprising two tandemly oriented GLP-1(7-36(A8G)) polypeptides fused via its C-terminus to the N-terminus of albumin comprising SEQ ID NO:327 wherein said human is obese.
A method of treating obesity in a human comprising administering to said human a pharmaceutical composition comprising an albumin fusion protein produced by a host cell comprising construct ID 3070, which is contained in ATCC deposit No. PTA-4671.
Dependencies are inferred from the claim text.